Small-molecule generic drugs account for a lion's share of the market, while biosimilars exhibit fastest growth, per a new report from ReasearchAndMarkets.com.
Danny Sanchez, CEO of EmpirRx Health, discusses how it is different than other well-known PBMs and how the company puts patients first through its clinically driven model.
Walgreens Specialty Pharmacy expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for the retailer's pharmacy business.
HB 4149 will provide Oregon with enforcement authority, requiring PBMs to be licensed by the Oregon Department of Consumer and Business Services starting Jan. 1, 2025.